erenumab-aooe
Study Shows Anti-CGRP Monoclonal Antibody Agents as Future Treatment for Neuropathic Pain
A study has used a novel approach to treat neuropathic pain effectively with monoclonal antibodies that block ...
AUGUST 25, 2021
Patients Report Long-Term Reduction in Episodic Migraine Frequency With Erenumab
Sustained reductions in migraine frequency over more than four years were found with use of erenumab (Aimovig, ...
AUGUST 13, 2019
FDA Approves New Preventive Injection for Migraine
The FDA approved the first preventive injection for migraine, erenumab-aooe, a once-monthly self-injection, ...
MAY 18, 2018
Load more